Fritextsökning
Innehållstyper
-
Mingling do's and don'ts
Linkedin, Facebook, MSN and Gmail are all perfect tools for the urban businessman or woman to keep track of and stay up-to-date with contacts. "But in the end, ...
-
Lytix calls in cash
Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.
-
New tools to fight bacteria
Better guidelines for doctors, detailed patient journals, and national monitoring systems are some of the tools needed to combat the increasing problem of antib...
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten ...
-
Tre diagnostikbolag slås ihop
Almi Invest investerar i en svensk-finsk företagsfusion med målet att få fram produkter för snabbare och säkrare analyssvar i sjukvården.
-
Infidelity produces faster sperms
Until now, it has been difficult to prove that fast-swimming sperms have an advantage when it comes to fertilizing an egg.
-
Första priset efter rekorddonationen
I maj 2016 donerade Bengt Sjöberg 2 miljarder kronor - en av de största donationerna i svensk historia. Nu delas det första priset i donationens namn ut. Sjöber...
-
A crash course in IP strategy
"Publish, publish, publish!" Sound familiar? So to meet the researcher's wishes, do you scribble a patent application with lipstick on a napkin and send it in? ...
-
Säkerhetsbrister på barnsjukhus
Knäckte lösenorden till skyddade dokument från prövningar
-
Schizophrenia and bipolar disorder are relatives
Schizophrenia and bipolar disorder have the same genetic causes, according to a study from Karolinska Institutet.
-
Nytt namn i Symphogens ledning
Adriann Sax har utsetts till affärschef på det danska företaget.
-
Academy for a new turn at work
Are you qualified within life science, but unemployed? Here is your chance for a new career, in high demand.
-
Nobel Biocare får ny marknadschef
Hans Geiselhöringer tar över från tidigare marknadschefen, som istället kommer att fokusera på företagets nyckelkunder.
-
Less scars with new product
A new Swedish product for post surgical scar formation enters clinical development.
-
Halo genomics blir amerikanskt
Agilent technologies köper upp Uppsalaföretaget.
-
Två Allenex-bolag gör exit
Schweiziskt bolag tar över innehavet i Novahep och Recopharma.
-
Swedish cancer therapy granted
Pledpharma, Linköping University and Ryhov County Hospital receive a research grant from the Research Council FORSS to conduct clinical studies in cancer patients.
-
Diamyd förlikar i licenstvist
Ger University of Florida en del av ersättningen de fick från affären med Ortho-McNeil-Janssen.
-
Sanionas kokainstudie inledd
Bioteknikföretagets samarbetspartner TRC har påbörjat rekrytering till studien om kokainberoende.
-
Apoteket gets new vice CEO
The Swedish government company Apoteket has recently appointed a vice CEO.
-
EMA tillsätter expertgrupp mot Zika
Erbjuder rådgivning kring vetenskapliga och regulatoriska frågor till bolag som utvecklar läkemedel och vaccin mot viruset.
-
Time to save for survival
The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.
-
Norwegian cancer therapy leaves phase II
New clinical results from Algeta highlights the potential of Alpharadin to treat bone metastases in major cancer indications.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
BREAKING